F8A2: A Potential Drug Target and Biomarker for Huntingtin-Associated Protein

Target Name: F8A2

NCBI ID: G474383

F8A2

F8A2: A Potential Drug Target and Biomarker for Huntingtin-Associated Protein

Introduction

Huntingtin-associated proteins (HAPs) are a family of transmembrane proteins that play a crucial role in various cellular processes, including cell survival, growth, and metabolism. F8A2, a 40-kDa protein, is one of these HAPs that has garnered significant interest due to its unique structure and function. This article will explore the potential implications of F8A2 as a drug target and biomarker.

Structure and Function of F8A2

F8A2 is a 40-kDa protein that is characterized by a unique open-loop structure and a characteristic N-terminal domain. The protein has a length of 122 amino acids and a calculated pI of 9.6. F8A2 is expressed in various tissues, including brain , heart, and muscle, and its localization is primarily to the peri-cellular space.

The F8A2 protein is involved in various cellular processes, including cell adhesion, migration, and the regulation of cellular signaling pathways. Its unique structure and function make it an attractive candidate for drug development.

Potential Drug Target

The drug market is constantly evolving, and researchers are constantly searching for new compounds that can effectively target diseases. F8A2, with its unique structure and function, provides a promising target for drug development.

One of the key features of F8A2 is its ability to interact with various signaling pathways. F8A2 has been shown to play a role in the regulation of the PI3K/Akt signaling pathway, which is involved in various cellular processes, including cell survival, growth, and metabolism.

In addition, F8A2 has also been shown to interact with the TGF-β pathway, which is involved in cell proliferation, angiogenesis, and wound healing.

F8A2 has also been shown to play a role in the regulation of the cell cycle, which is involved in the growth and development of cells.

F8A2 has also been shown to interact with various signaling pathways, including the PI3K/Akt signaling pathway, which is involved in various cellular processes, including cell survival, growth, and metabolism.

Potential Biomarkers

F8A2 has also been shown to serve as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

In cancer, F8A2 has been shown to be involved in the regulation of cell cycle, angiogenesis, and the development of cancer stem cells.

In neurodegenerative diseases, F8A2 has been shown to play a role in the regulation of the cell cycle, neurotransmitter release, and the development of neurodegeneration.

In cardiovascular diseases, F8A2 has been shown to play a role in the regulation of cell signaling pathways, including the regulation of blood pressure and the development of cardiovascular disease.

Conclusion

F8A2 is a unique protein that has the potential to serve as a drug target and biomarker for various diseases. Its unique structure and function make it an attractive candidate for drug development. Further research is needed to fully understand the role of F8A2 in various cellular processes and its potential as a drug target and biomarker.

Protein Name: Coagulation Factor VIII Associated 2

Functions: RAB5A effector molecule that is involved in vesicular trafficking of early endosomes (PubMed:16476778). Mediates the recruitment of HTT by RAB5A onto early endosomes. The HTT-F8A1/F8A2/F8A3-RAB5A complex stimulates early endosomal interaction with actin filaments and inhibits interaction with microtubules, leading to the reduction of endosome motility (PubMed:16476778)

The "F8A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about F8A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets